A Study of LY2523355 in Patients With Solid Cancer
The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.
Solid Tumors
DRUG: LY2523355
Dose limiting toxicity based on the Common Terminology Criteria for Adverse Events v4.0|Number of patients with adverse events
Pharmacokinetics, Plasma concentration of LY2523355 and metabolite|Antitumor effect, Response evaluation criteria in solid tumors
The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer. The secondary objectives are to study the pharmacokinetics and antitumor effect.